转移性结直肠癌的治疗进展。
Advances in the treatment of metastatic colorectal cancer.
机构信息
Department of Hematology/Oncology, University of Oklahoma, Oklahoma City, OK, USA.
出版信息
Am J Ther. 2009 Sep-Oct;16(5):412-20. doi: 10.1097/MJT.0b013e3181907ed9.
Abstract
The treatment of metastatic colorectal cancer has undergone major advances yielding significant improvements in survival over the past decade. These advances have evolved due to the benefits of combination chemotherapy and the incorporation of biologic therapy. However, as we struggle to provide optimum care while sparing patients ineffective therapy and undue cost, the importance of tailored therapy to maximize benefit will become increasingly important. This article reviews the major advances in the treatment of patients with metastatic colorectal cancer and the burgeoning developments in individualized therapy.
摘要
过去十年中，转移性结直肠癌的治疗取得了重大进展，显著提高了患者的生存率。这些进展源于联合化疗的益处和生物治疗的应用。然而，随着我们努力在为患者提供最佳治疗的同时避免无效治疗和不必要的成本，针对患者进行个体化治疗以实现最大获益的重要性将日益凸显。本文回顾了转移性结直肠癌治疗方面的主要进展以及个体化治疗方面的新兴发展。
相似文献
1
Advances in the treatment of metastatic colorectal cancer.转移性结直肠癌的治疗进展。
Am J Ther. 2009 Sep-Oct;16(5):412-20. doi: 10.1097/MJT.0b013e3181907ed9.
2
Metastatic colorectal cancer: recent advances in its clinical management.转移性结直肠癌：临床管理的最新进展。
Expert Rev Anticancer Ther. 2009 Dec;9(12):1829-47. doi: 10.1586/era.09.143.
3
Treatment of metastatic colorectal cancer.转移性结直肠癌的治疗。
Semin Oncol. 2011 Aug;38(4):552-60. doi: 10.1053/j.seminoncol.2011.05.009.
4
Current opinion on optimal treatment for colorectal cancer.当前关于结直肠癌最佳治疗方法的观点。
Expert Rev Anticancer Ther. 2013 May;13(5):597-611. doi: 10.1586/era.13.37.
5
An update on treatment advances for the first-line therapy of metastatic colorectal cancer.转移性结直肠癌一线治疗的治疗进展更新
Cancer J. 2007 Sep-Oct;13(5):276-81. doi: 10.1097/PPO.0b013e3181570062.
6
An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma.转移性结直肠癌随机临床试验的最新进展
Surg Oncol Clin N Am. 2017 Oct;26(4):667-687. doi: 10.1016/j.soc.2017.05.007. Epub 2017 Aug 4.
7
Directions for further improvements of treatment of metastatic colorectal cancer.转移性结直肠癌治疗的进一步改进方向。
Scand J Gastroenterol. 2012 Mar;47(3):363-4. doi: 10.3109/00365521.2012.640837. Epub 2011 Dec 19.
8
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.转移性结直肠癌最佳全身治疗的当前观点：ACTG/AGITG专家会议（2013年欧洲肿瘤内科学会）的结果
Expert Rev Anticancer Ther. 2014 Dec;14(12):1477-93. doi: 10.1586/14737140.2014.949678. Epub 2014 Aug 20.
9
Biologic therapies in colorectal cancer: indications and contraindications.结直肠癌的生物治疗：适应证与禁忌证
Am Soc Clin Oncol Educ Book. 2015:e197-206. doi: 10.14694/EdBook_AM.2015.35.e197.
10
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.基于卡培他滨的化疗在转移性结直肠癌中的药物经济学效益。
J Clin Oncol. 2008 May 1;26(13):2224-6; author reply 2228. doi: 10.1200/JCO.2008.16.2826.
引用本文的文献
1
Hydroxychloroquine-Loaded Chitosan Nanoparticles Induce Anticancer Activity in A549 Lung Cancer Cells: Design, BSA Binding, Molecular Docking, Mechanistic, and Biological Evaluation.载羟氯喹壳聚糖纳米粒诱导 A549 肺癌细胞的抗癌活性：设计、BSA 结合、分子对接、机制和生物学评价。
Int J Mol Sci. 2023 Sep 14;24(18):14103. doi: 10.3390/ijms241814103.
2
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer.转移性结直肠癌中每周与每两周一次西妥昔单抗给药的真实世界比较。
J Comp Eff Res. 2023 Feb;12(2):e220143. doi: 10.2217/cer-2022-0143. Epub 2023 Jan 27.
3
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.regorafenib 在结直肠癌细胞中诱导衰老和上皮间质转化以促进耐药性。
Cells. 2022 Nov 18;11(22):3663. doi: 10.3390/cells11223663.
4
Inoperable metastatic colorectal cancer with primary tumour : Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).伴有原发性肿瘤的不可切除转移性结直肠癌：评估原发性肿瘤和转移部位对一线全身治疗的不一致反应以及原发性肿瘤引起的并发症（来自爱尔兰癌症中心的经验）
Mol Clin Oncol. 2022 Feb;16(2):40. doi: 10.3892/mco.2021.2472. Epub 2021 Dec 21.
5
Molecular Targets of Natural Compounds with Anti-Cancer Properties.具有抗癌特性的天然化合物的分子靶点。
Int J Mol Sci. 2021 Dec 20;22(24):13659. doi: 10.3390/ijms222413659.
6
Navigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix.在美国探索转移性结直肠癌的治疗选择：一项关于患者对 Vectibix 相关皮肤毒性的接受程度的调查。
Support Care Cancer. 2021 Nov;29(11):6731-6740. doi: 10.1007/s00520-021-06134-8. Epub 2021 May 11.
7
A Systematic Literature Review and Meta-Analysis Describing the Prevalence of , and Gene Mutations in Metastatic Colorectal Cancer.一项描述转移性结直肠癌中 、 和 基因突变发生率的系统文献综述与荟萃分析。 （原文中“ , and ”处信息缺失，需补充完整相关基因名称才能准确翻译）
Gastroenterology Res. 2020 Oct;13(5):184-198. doi: 10.14740/gr1167. Epub 2020 Oct 8.
8
LncRNAs as Regulators of Autophagy and Drug Resistance in Colorectal Cancer.长链非编码RNA作为结直肠癌自噬和耐药性的调节因子
Front Oncol. 2019 Oct 2;9:1008. doi: 10.3389/fonc.2019.01008. eCollection 2019.
9
The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics.转移性结直肠癌患者中靶向表皮生长因子受体的单克隆抗体药物相关输液反应的发生率：一项系统文献回顾和患者及研究特征的荟萃分析。
Cancer Med. 2019 Sep;8(12):5800-5809. doi: 10.1002/cam4.2413. Epub 2019 Aug 3.
10
A novel curcumin analog inhibits canonical and non-canonical functions of telomerase through STAT3 and NF-κB inactivation in colorectal cancer cells.一种新型姜黄素类似物通过使结直肠癌细胞中的信号转导和转录激活因子3（STAT3）及核因子κB（NF-κB）失活来抑制端粒酶的经典和非经典功能。
Oncotarget. 2019 Jul 16;10(44):4516-4531. doi: 10.18632/oncotarget.27000.
本文引用的文献
1
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.UGT1A1*28基因型与转移性结直肠癌患者的伊立替康剂量：一项荷兰结直肠癌研究组的研究
Br J Cancer. 2008 Jul 22;99(2):275-82. doi: 10.1038/sj.bjc.6604461. Epub 2008 Jul 1.
2
EGFR FISH in colorectal cancer: what is the current reality?结直肠癌中的表皮生长因子受体荧光原位杂交技术：当前现状如何？
Lancet Oncol. 2008 May;9(5):402-3. doi: 10.1016/S1470-2045(08)70109-8.
3
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.基于药代动力学随访的氟尿嘧啶个体化剂量调整与传统剂量比较：转移性结直肠癌患者多中心随机试验结果
J Clin Oncol. 2008 May 1;26(13):2099-105. doi: 10.1200/JCO.2007.13.3934.
4
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.野生型KRAS是帕尼单抗对转移性结直肠癌患者疗效所必需的。
J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.
5
Determinants of RASistance to anti-epidermal growth factor receptor agents.RAS对抗表皮生长因子受体药物耐药性的决定因素。
J Clin Oncol. 2008 Apr 1;26(10):1582-4. doi: 10.1200/JCO.2007.15.3700. Epub 2008 Mar 3.
6
Cancer statistics, 2008.2008年癌症统计数据。
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
7
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.一项关于卡培他滨、奥沙利铂和贝伐单抗联合或不联合西妥昔单抗用于一线晚期结直肠癌的随机III期研究，即荷兰结直肠癌组（DCCG）的CAIRO2研究。毒性的中期分析。
Ann Oncol. 2008 Apr;19(4):734-8. doi: 10.1093/annonc/mdm607. Epub 2008 Feb 13.
8
Cetuximab for the treatment of colorectal cancer.西妥昔单抗用于治疗结直肠癌。
N Engl J Med. 2007 Nov 15;357(20):2040-8. doi: 10.1056/NEJMoa071834.
9
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.表皮生长因子受体荧光原位杂交检测可预测化疗难治性结直肠癌患者对西妥昔单抗的反应。
Ann Oncol. 2008 Apr;19(4):717-23. doi: 10.1093/annonc/mdm492. Epub 2007 Oct 31.
10
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.伊立替康联合持续静脉输注、大剂量推注或口服氟嘧啶用于转移性结直肠癌一线治疗的随机对照试验：BICC-C研究结果
J Clin Oncol. 2007 Oct 20;25(30):4779-86. doi: 10.1200/JCO.2007.11.3357.
Zotero 插件